Baker Bros. Advisors Lp bought $9.5M of Celcuity (CELC)
Executed Sep 8 2025, disclosed Sep 10 2025, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Sep 10 2025), the stock returned -18.2% (delay-adjusted); from the execution session (Sep 8 2025), -14.3%. Derived: entry at the session's open, exit at the close 20 sessions later.
Baker Bros. Advisors Lp (Other) filed 10 Form 4 reports as a reporting entity in the trailing twelve months (9 purchases, 1 sale), most often in Kodiak Sciences Inc. (KOD). Across 7 priced purchase filings, the average 21-session return was +27.3% from execution and +5.7% from disclosure (delay-adjusted; derived). The largest single filing was $317.8M of CELC (3,100,000 sh across 2 lots, as filed), executed Jul 14.
Healthcare · Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→3,100,000 sh across 2 lots
Exec Jul 14
Filed Jul 16 · 5:42 PM ET